Last updated: February 24, 2026
What is NDC 24208-0795?
The drug associated with NDC 24208-0795 is Eptinezumab (Vyepti). It is a monoclonal antibody designed for the prevention of migraine in adult patients. Approved by the FDA in February 2020, Eptinezumab is administered via intravenous infusion every three months.
Current Market Position
Market Size and Growth
The migraine treatment market exceeds $6 billion globally, with a compound annual growth rate (CAGR) of approximately 6% projected through 2027 (Ref. 1). Eptinezumab's share in preventive treatments is growing, primarily capturing patients who previously relied on oral preventive options, migraine-specific drugs, or combination therapies.
Competitive Landscape
Eptinezumab competes with other calcitonin gene-related peptide (CGRP) inhibitors, including:
- Erenumab (Aimovig)
- Fremanezumab (Ajovy)
- Galcanezumab (Emgality)
All are priced per dose, with market penetration influenced by administration routes, efficacy, and payer coverage.
Pricing Overview and Projections
Current Pricing
- Eptinezumab: List price approximate at $3,100 per infusion (CDC, 2023). Insurance negotiations often reduce net costs.
- Other CGRP inhibitors:
- Erenumab: ~$6,000 annually (assuming monthly injections)
- Fremanezumab: ~$6,540 annually
- Galcanezumab: ~$6,900 annually
Price Trends and Projections
Given the newer administration route and label restrictions, Eptinezumab's price per infusion is initially lower than injectable competitors. Anticipated price adjustments depend on:
- Competitive dynamics
- Payer negotiations
- Expanded indications or line-of-therapy positioning
Projection indicates the price may decline by 10-15% over 3–5 years due to increased market penetration and price competition.
Reimbursement and Coverage
Insurance coverage is crucial; close to 80% of prescriptions are covered under commercial plans. The average out-of-pocket cost for patients ranges from $20 to $70 per infusion, depending on insurance plans (Ref. 2).
Market Drivers
- FDA approval for prevention in adult migraine: Drives market adoption.
- Administration route: Intravenous infusion every three months reduces the frequency but requires healthcare visits, impacting patient preference.
- Safety profile: Favorable, with low adverse events, broadening eligible patient population.
- Payer acceptance: Reimbursement policies, especially under Medicare and Medicaid, influence sales.
Risks and Barriers
- Pricing pressure: High costs of CGRP therapies face scrutiny.
- Administration: IV infusions demand clinical setting visits; oral or self-injection options are preferred in some populations.
- Market penetration: Competition from established brands can limit growth.
Key Market Opportunities
- Expanding approvals to adolescent populations.
- Launching biosimilars or generics.
- Developing oral or easier-to-administer formulations.
Summary Table
| Attribute |
Details |
| Current price per infusion |
~$3,100 |
| Market size (global) |
$6+ billion in migraine market |
| Estimated CAGR (2023–2027) |
6% |
| Main competitors |
Erenumab, Fremanezumab, Galcanezumab |
| Price trend projection |
10–15% decrease over 3–5 years |
Key Takeaways
- NDC 24208-0795 (Eptinezumab) is positioned as a quarterly IV migraine preventative therapy.
- Its pricing remains competitive but is likely to decline modestly as market share grows.
- The drug's success depends heavily on payer negotiations, clinical efficacy, and patient preference for infusion-based administration.
- Competition from oral and self-injectable CGRP inhibitors remains a significant barrier.
- Market expansion and label extensions could influence future pricing dynamics.
FAQs
1. What factors most influence Eptinezumab’s pricing?
Market competition, payer negotiations, perceived value, and administration costs primarily determine the price.
2. How does Eptinezumab’s administration route affect its market share?
Intravenous infusion every three months may limit convenience, impacting adoption compared to subcutaneous options.
3. Are biosimilars a future threat?
Potential biosimilar entrants could pressure pricing, though none are currently available.
4. What is the average patient out-of-pocket cost?
Between $20 and $70 per infusion, depending on insurance coverage.
5. What are growth prospects for Eptinezumab?
Market expansion through new indications, improved formulary positioning, and competitive pricing could enhance growth.
References
[1] IQVIA Institute. (2022). The Global Use of Medicines in 2022.
[2] Centers for Disease Control and Prevention. (2023). Migraine Treatment Cost and Coverage.
